Key result
Adding SGLT2 inhibitors, nonsteroidal MRAs, or GLP-1 RAs to renin angiotensin system inhibitors reduces CKD progression and cardiovascular events in patients with CKD.
Why the study?
With multiple effective treatments now available to slow chronic kidney disease progression beyond renin angiotensin system inhibitors, this review considers their mechanisms, benefits, and the challenges of achieving optimal combination therapy.
Novel therapies including SGLT2 inhibitors, nonsteroidal MRAs, and GLP-1 RAs provide additive kidney and cardiovascular protection in patients with CKD, highlighting the need for optimal combination therapy.
No takes yet. Share an insight, caveat, or question.
Multiple CKD therapies now available beyond RAS inhibition; leaves open optimal combination strategies for practice and trials.
Maarten W. Taal (2024) conducted a review in Chronic kidney disease (CKD). SGLT2 inhibitors, nonsteroidal mineralocorticoid antagonists, and GLP-1 receptor agonists was evaluated. Adding SGLT2 inhibitors, nonsteroidal MRAs, or GLP-1 RAs to renin angiotensin system inhibitors reduces CKD progression and cardiovascular events in patients with CKD.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: